BD Gene Therapeutics
Minhang
About BD Gene Therapeutics
BD Gene Therapeutics is a provider of a gene-editing platform for the treatment of genetic diseases. It uses mRNA delivery technology to achieve safe and efficient delivery of gene-editing tools such as CRISPR. In addition, BD-mRNA technology has important application prospects in the fields of tumor immunity and regenerative medicine. It also uses the fourth-generation lentiviral vector platform for all types of cells. It has developed antiviral eyedrops and others.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $29.1M
- Funding stage: Early Stage Venture
- Last round: Series B (Jun 2023)
- Website: bdgenetherapeutics.com
- Phone: 17721291876
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/bd-gene-therapeutics-87620 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.